Navigation Links
Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/5/2009

SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the three and nine months ended September 30, 2009.

Based upon the Priority Review designation granted by the FDA for Cadence's New Drug Application (NDA) for Acetavance(TM) (intravenous acetaminophen), the company accelerated its commercial readiness activities during the third quarter of 2009. Commenting on the third quarter achievements, Ted Schroeder, President and CEO of Cadence stated, "We are extremely pleased with the progress we have made in building our commercial infrastructure, including the recruitment of a highly experienced commercial leadership team to launch Acetavance, if approved by the FDA."

Financial Results

For the three months ended September 30, 2009, Cadence reported a net loss of $11.4 million, or $0.23 per share, compared to a net loss of $13.7 million, or $0.36 per share, for the same period in 2008. Operating expenses for the three months ended September 30, 2009 decreased $2.4 million to $11.3 million, from the $13.7 million reported for the comparable period in 2008. The decline in operating expenses during the current year was primarily the result of a reduction in research and development costs as the company completed its clinical development program for Acetavance in early 2009 and submitted an NDA for this product candidate in May 2009. Further, in March 2009, the company discontinued the development program for its omiganan product candidate. Partially offsetting this reduction is an increase in sales and marketing expenses as the company focused significant resources on establishing its com
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Canaccord Adams Global Growth Conference in Boston on August 11, 2009
3. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
4. Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
8. Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
9. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
11. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... February 28, 2015 A case management ... lawsuits that have been filed by law firms including ... week in March, the Firm notes. , According ... involved in the federal litigation will meet on March ... to prescription therapy treatments designed to raise levels of ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 On Thursday, February ... Make It Easy For Scammers To Steal Your Data , ... get their hands on a DIY phishing kit, or any ... also touched on another important point about how everyone’s cyber ... are often implemented, “like compromising legitimate content management systems or ...
(Date:2/28/2015)... 28, 2015 Developers of FCPX ... new overlay plugin for Final Cut Pro X entitled FCPX ... Overlay Chromatic gives users total control over 6k lens dirt ... of Pixel Film Studios. “FCPX Overlay Chromatic was professionally designed ... use interface.” , FCPX Overlay Chromatic Grunge 6K is a ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Plugin creators ... TransFold Volume 2. A fully customizable transition ... “TransFold Volume 2 gives users total control over 30 ... Austin, CEO of Pixel Film Studios. “TransFold Volume 2 ... editor.” , TransFold Volume 2 from Pixel Film Studios ...
(Date:2/28/2015)... My Shiney Hiney® LLC., the renowned brand in personal ... Nevada for the annual ASD Market Week tradeshow. , ... tradeshows and My Shiney Hiney will be one of the ... can be found at booth number C1663. , My Shiney ... hygiene brush and cleansing system exclusively created to clean and ...
Breaking Medicine News(10 mins):Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2
... Healthcare is an industry faced with unprecedented uncertainty. ... overcome the noise and clearly communicate relevant and timely ... company Griffin York & Krause (GY&K) reaffirmed its commitment ... been honored with six national CardioVascular Advertising (CVA) Awards. ...
... Nov. 12 First Citizens Bank, a premier full-service ... into an agreement to provide a patient payment system ... , mPay Gateway,s software solution enables health care providers ... service and obtain payment authorization before a patient leaves ...
... abnormal cells in milk ducts, study finds , THURSDAY, Nov. ... may be driving down rates of a condition called "atypical ... research suggests. , This is the first time a link ... in the breast,s milk ducts -- and hormone therapy, said ...
... TORONTO, Ont., November 12, 2009 As more Canadians are ... hospital. The most severely affected may be treated in the ... to help them breathe while they recover from the infection. ... people felled by serious illness, in some cases, this supportive ...
... ... Medical Trust and Milton Cato Memorial Hospital, announces the appointment of Dr. Ty-Asha Plummer ... well as to the Clinical Faculty of Trinity School of Medicine. , ... (PRWEB) November 12, 2009 ...
... HealthyOutcomes.com ... ... Diabetes Foundation estimates 344 million people in the world are at risk for Type 2 ... twice. 285 million already suffer from the disease, a growing epidemic. , , , ...
Cached Medicine News:Health News:Healthcare Organizations Face Tough Marketing Challenges - GY&K Asks 'Are You Relevant?' 2Health News:Healthcare Organizations Face Tough Marketing Challenges - GY&K Asks 'Are You Relevant?' 3Health News:First Citizens Bank to Offer mPay Gateway's Point-of-Care Patient Payment System to Its Health Care Customers 2Health News:Less HRT, Fewer Cases of Possible Breast Cancer Precursor 2Health News:Less HRT, Fewer Cases of Possible Breast Cancer Precursor 3Health News:Mechanical ventilation for patients with lung damage don't always work as planned 2Health News:Mechanical ventilation for patients with lung damage don't always work as planned 3Health News:Trinity School of Medicine Announces the Appointment of Ty-Asha Plummer, M.D. to the Clinical Faculty 2Health News:Trinity School of Medicine Announces the Appointment of Ty-Asha Plummer, M.D. to the Clinical Faculty 3Health News:In Time for World Diabetes Day, November 14, 2009 - New Website Empowers Diabetes Patients to Learn and Earn 2
(Date:2/27/2015)... NEW YORK , Feb. 27, 2015  Pomerantz ... Vitae Pharmaceuticals, Inc. ("Vitae" or the "Company") (NASDAQ: ... Robert S. Willoughby at rswilloughby@pomlaw.com ... whether Vitae and certain of its officers and/or directors ... Exchange Act of 1934.  On February ...
(Date:2/27/2015)... YORK , Feb. 27, 2015 Securities ... the board of Salix Pharmaceuticals, Ltd. (NASDAQ: ... $158.00 per share. Concerned SLXP investors are encouraged to ... The investigation focuses upon the shareholder ... agreement, Salix shareholders would receive only $158.00 per share ...
(Date:2/27/2015)... -- Report Details   Translational ... progress, and predicted revenues ,Where is the market for ... prospects for this market and related technologies? Visiongain,s brand ... to 2025, discussing data, opportunities and prospects. ... medicine : cell-based therapies that aim to restore function ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... 8, 2010 Substandard and counterfeit versions of thirteen ... Ghana by the Medicines Quality Monitoring surveillance program. Set ... in collaboration with the U.S. Pharmacopeial Convention (USP) and ... samples antimalarials across the public and private sectors. It ...
... WEST PALM BEACH, Fla., Nov. 8, 2010 ... Use and Health, teens abuse prescription medications more ... teens are under the misconception that these highly ... drugs. (Logo: http://photos.prnewswire.com/prnh/20100901/FL58348LOGO) ...
Cached Medicine Technology:Substandard and Counterfeit Antimalarial Drugs in Ghana Discovered by Cooperative Program of USP, Ghana Food and Drugs Board 2Substandard and Counterfeit Antimalarial Drugs in Ghana Discovered by Cooperative Program of USP, Ghana Food and Drugs Board 3Abuse Of Prescription Meds Among Teens Greater Than Most Illegal Drugs 2Abuse Of Prescription Meds Among Teens Greater Than Most Illegal Drugs 3
... is a unique microprocessor controlled shaking incubator ... either 96 or 384 well format. Speed, ... control panel and all are displayed on ... the clear protective cover. The Millennium 2000 ...
... the only four-color, automated benchtop flow cytometry ... cell sorting. Designed specifically to support a ... offers software instrument control, auto-sample loading, and ... productivity. FACSCalibur is fully modular so it ...
... Ultracompact high end desktop multilaser flow ... any kind of cell analysis and absolute ... forward and two different side scatter signals ... channels. The new CyFlow ML instrument can ...
This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
Medicine Products: